Journal «Angiology and Vascular Surgery» • 

2012 • VOLUME 18 • №2

On advisability of perioperative phleboprotection in endovascular treatment of lower in varicose disease: first initial results of the decision study

Bogachev V.Yu., Golovanova O.V., Kuznetsov A.N., Shekoyan L.O. and the DECISION Study Group

Scientific Research Institute of Clinical Surgery at the Russian State Medical University, Moscow, Russia

Presented in the article are the results of the DECISION multicenter study dedicated io assessment of efficacy and feasibility of using the phlebotropbic drug detralex in the perioperative period in patients undergoing endovascular treatment of lower limb varicose discase. The study comprised a total of 230 patients presenting with chronic venous disease. (CVD) C2-4s according the CEAP classification, each of these had not less than three CVD- related symptoms. All patients were randomly assigned to the Study Group (126 people) and the Control Group (104 subjects). The Study Group patients 2 weeks prior to endovascular treatment and during 4 weeks thereafter took the phlebotrophic drug detralex at a standard daily dose of 1,000 mg. The Control Group patients received conventional compression thernpy using compression bandages or medicinal knitted fabric. The findings of the statistically processed results in the both groups demonstrated a significant decrease in the CVD severity score according to the VCSS scale and an increase in the quality of life parameters according to the disease-specilic questionnaire CIVIQ-14. While so doing, more pronounced dynamics was observed in patients taking detralex during the perioperative period. Besides, there was synergism between the results of the endovascular intervention and therapeutic effects from detralex. Based on the findings obtained in the present study, the authors made a conclusion on feasibility of using the drug detralex as an agent for nonspecific pharmacological protection in endovascular treatment of varicose disease.

KEY WORDS: Detralex, varicose disease, endovascular treatment, pharmacological orotection.

P. 90-95

« Back